Gene therapy approaches to ventricular tachyarrhythmias

Journal of Electrocardiology

Volumn 40, Issue 6 SUPPL. 1, 2007, Pages

  Donahue, J Kevin ^a   Sasano, Tetsuo ^a   Kelemen, Kamilla ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Arrhythmia; Gene therapy; Myocardial infarction; Potassium channel; Ventricular tachycardia

Indexed keywords

ADENOSINE; ADENOVIRUS VECTOR; BETA GALACTOSIDASE; GANCICLOVIR; GLYCERYL TRINITRATE; TADALAFIL; VASCULOTROPIN;

ARTICLE; CONTINUOUS INFUSION; GENE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE TACHYCARDIA; KCNH2 G628S GENE; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SCAR; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; DISEASE MODELS, ANIMAL; ETHER-A-GO-GO POTASSIUM CHANNELS; GENE THERAPY; HUMANS; SWINE; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 35748938760     PISSN: 00220736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2007.05.036     Document Type: Article

References (25)

1. American Heart Association. 2001 Heart and stroke statistical update (2002), American Heart Association, Dallas (Tex)
2. Maisel W., Moynahan M., Zuckerman B., et al. Pacemaker and ICD generator malfunctions. JAMA 295 (2006) 1901
3. Gould P., Krahn A., and Canadian Heart Rhythm Society Working Group on Device Advisories. Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories. JAMA 295 (2006) 1907
4. Estes N. Primary prevention of sudden cardiac death: a rational approach to the use of the implantable cardioverter defibrillator. J Interv Cardiol EP 13 (2005) 91
5. Sasano T., McDonald A., Kikuchi K., and Donahue J.K. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat Med 12 (2006) 1256
6. Flotte T., Afione S., Conrad C., et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci U S A 94 (1993) 10613
7. Jiang H., Lillicrap D., Patarroyo-White S., et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108 (2006) 107
8. Arruda V., Stedman H., Nichols T., et al. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 105 (2005) 3458
9. Muhlhauser J., Jones M., Yamada I., et al. Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. Gene Ther 3 (1996) 145
10. Kass-Eisler A., Falck-Pedersen E., Alvira M., et al. Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc Natl Acad Sci U S A 90 (1993) 11498
11. Delacretaz E., and Stevenson W. Catheter ablation of ventricular tachycardia in patients with coronary heart disease. Part II: clinical aspects, limitations, and recent developments. Pacing Clin Electrophysiol 24 (2001) 1403
12. Calkins H., Epstein A., Packer D., et al. Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. J Am Coll Cardiol 35 (2000) 1905
13. Donahue J.K., Kikkawa K., Johns D., Marban E., and Lawrence J. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci U SA 94 (1997) 4664
14. Donahue J.K., Kikkawa K., Thomas A.D., Marban E., and Lawrence J. Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Ther 5 (1998) 630
15. Nagata K., Marban E., Lawrence J., and Donahue J.K. Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium. J Mol Cell Cardiol 33 (2001) 575
16. Sasano T., Kikuchi K., Feng N., McDonald A., Lai S., and Donahue J.K. Targeted high-efficiency, homogeneous myocardial gene transfer. J Mol Cell Cardiol 42 (2007) 954
17. Zhou Z., Gong Q., Ye B., et al. Properties of HERG channels stably expressed in HEK293 cells studied at physiological temperature. Biophys J 74 (1998) 230
18. Echt D., Liebson P., Mitchell L., et al. Cardiac arrhythmia suppression trial investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med 324 (1991) 781
19. Waldo A., Camm A., deRuyter H., et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 348 (1996) 7
20. Moss A., Zareba W., Hall W., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877
21. Kadish A., Dyer A., Daubert J., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004) 2151
22. Bardy G., Lee K., Mark D., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225
23. Donahue J.K., Heldman A., Fraser H., et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med 6 (2000) 1395
24. Miake J., Marban E., and Nuss H. Biological pacemaker created by gene transfer. Nature 419 (2002) 132
25. Qu J., Plotnikov A., Danilo P.J., et al. Expression and function of a biological pacemaker in canine heart. Circulation 107 (2003) 1106